Relief for long-suffering investors in Mela Sciences (MELA +4.1%) may soon be at hand, Barron's...

|By:, SA News Editor
Relief for long-suffering investors in Mela Sciences (MELA +4.1%) may soon be at hand, Barron's writes. The maker of a promising device for diagnosis cancer said last week that the FDA had finally issued an "approvals letter," which analysts say should help it resolve all remaining issues before a final vote.